Our laboratory focuses on deciphering the molecular mechanisms underlying aberrant cell signaling events that contribute to tumorigenesis including but not limited to the oncogenic mTOR/Akt pathway. Understanding these events may lead to identification of novel drug targets. Moving forward, we are also interested in developing new experimental systems and tools to further understand the interplays between key cancer signaling events to connect cancer signaling, metabolism and epigenetics, with the ultimate goal of identification and development new targeted therapies to combat human diseases.